Skip to content

Immix Biopharma, Inc. IMMX Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Allogene Therapeutics logo
Allogene TherapeuticsALLO
6.5%+0.2pp
Regenxbio logo
RegenxbioRGNX
$45.54M-12.6%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$8.19M+42.1%
Xencor logo
XencorXNCR
$36.82M-2.2%
Immunome logo
ImmunomeIMNM
$2.83M-32.1%
Precigen logo
PrecigenPGEN
11.4%-0.1pp

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s operating lease ROU assets?
Immix Biopharma, Inc. (IMMX) reported operating lease ROU assets of $927.73K in Q1 2026.
How has Immix Biopharma, Inc.'s operating lease ROU assets changed year-over-year?
Immix Biopharma, Inc.'s operating lease ROU assets increased by 1159659900.0% year-over-year, from $0.08 to $927.73K.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.